Tumor Local Microenvironment Is a Key Factor Affecting the Efficacy of PD-1 Inhibitor in Advanced Cervical Cancer: A Case Report and Literature Review
- 1 Department of Cancer, Donka National Hospital, Conakry Teaching Hospital, Conakry, Guinea
- 2 Department of Gynecologic Radiotherapy, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
- 3 Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China
- 4 Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China
- 5 Hebei Provincial Key Laboratory of Tumor Microenvironment and Drug Resistance, Shijiazhuang, China
- 6 Faculty of Health Sciences and Techniques of Gamal Abdel Nasser University of Conakry, Conakry, Guinea
- 7 Department of Gynecologic Radiotherapy, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
Abstract
Introduction: Conventional radiotherapy or chemotherapy is ineffective in the treatment of recurrent and metastatic cervical cancer. In recent years, immunotherapy has shown promise in the treatment of various solid tu mours, including cervical cancer. The overall response rate of the PD-1/PD-L1 inhibitor in cervical cancer is 14 % - 27%, and when combined with radiotherapy or conventional chemotherapy, the overall response rate can be further improved. Case presentation: We report here a case of a 49-year-old female patient presenting with two metastatic lesions of cervical cancer after postoperative radiotherapy, the first was located in the para-aortic region and the second in the presacral region. The enlarged para-aortic lymph nodes had not previ ously received radiotherapy, while the enlarged presacral lymph nodes had previously received postoperative radiotherapy. Treatment results showed that the recurrent presacral mass did not respond to the PD-1 inhibitor (camrelizumab) alone, whereas the metastatic para-aortic lymph nodes responded favourably to camrelizumab combined with low-intensity radiotherapy. Conclusion: PD1/PD-L1 inhibitors combined with radiotherapy should make it possible to overcome the bottleneck of conventional radiotherapy, improve patient prognosis or achieve better local control rates with lower radiotherapy doses.
- Puspitasari, I.M., Legianawati, D., Sinuraya, R.K., et al. (2021) Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients. International Journal of Women’s Health, 13, 221-229. https://doi.org/10.2147/IJWH.S289781
- Chung, H.C., Ros, W., Delord, J.P., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478. https://doi.org/10.1200/JCO.18.01265
- Wang, Y.M. and Li, G.L. (2019) PD-1/PD-L1 Blockade in Cervical Cancer: Current Studies and Perspectives. Frontiers of Medicine, 13, 438-450. https://doi.org/10.1007/s11684-018-0674-4
- Keita, M., Xi, C., Bah, M., Diallo, F.B., Fang, Z., et al. (2022) The Impact of Prophylactic Para-aortic Lymph Nodes Radiotherapy in Small Cell Carcinoma of the Cervix: A Case Report and Literature Review. Journal of Oncology Research and Treatment, 7, Article No. 4.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
- Dong, H.D., Strome, S.E., Salomao, D.R., et al. (2002) Tumor-Associated B7-H1 Promotes T-Cell Apoptosis: A Potential Mechanism of Immune Evasion. Nature Medicine, 8, 793-800. https://doi.org/10.1038/nm730
- Zheng, S., Lu, J.J., Liu, Y.H., et al. (2020) Synergistic Antitumor Effect on Cervical Cancer by Rational Combination of PD1 Blockade and CRISPR-Cas9-Mediated HPV Knockout. Cancer Gene Therapy, 27, 168-178. https://doi.org/10.1038/s41417-019-0131-9
- Kim, H.S., Kim, T., Lee, E.S., et al. (2013) Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis. Cancer Research and Treatment, 45, 193-201. https://doi.org/10.4143/crt.2013.45.3.193
- Liu, Y., Wu, L., Tong, R., et al. (2019) PD-1/PD-L1 Inhibitors in Cervical Cancer. Frontiers in Pharmacology, 10, Article No. 65. https://doi.org/10.3389/fphar.2019.00065
- Antonia, S.J., Villegas, A., Daniel, D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. The New England Journal of Medicine, 379, 2342-2350. https://doi.org/10.1056/NEJMoa1809697
- Kasmann, L., Taugner, J. and Manapov, F. (2019) Chemo-/Immuno-/Radiotherapy Combination in Treatment of Solid Cancer. Oncotarget, 10, 5387-5388. https://doi.org/10.18632/oncotarget.27141